论文部分内容阅读
本文通过微量全血、氚标记胸腺嘧啶掺入法测定１４名肿瘤患者和１４名正常人淋巴细胞的增殖反应。结果，肿瘤患者ＰＢＭＣ对ＰＨＡ诱导的增殖反应较正常人明显下降（Ｐ＜０．０１）。采用ＥＬＩＳＡ双抗体夹心法对其血浆（或血清）及ＰＨＡ诱导的７２ｈ淋巴细胞培养上清ｓＩＬ－２Ｒ含量检测。结果，肿瘤患者淋巴细胞培养上清ｓＩＬ－２Ｒ含量显著地低于正常对照组，其水平与淋巴细胞增殖反应呈正相关，其相关系数有非常显著意义（Ｔｒ＜０．０１）。而肿瘤患者外周血ｓＩＬ－２Ｒ含量显著地高于正常对照（Ｐ＜０．０１）。表明，肿瘤患者的Ｔ淋巴细胞表达、释放ＩＬ－２Ｒ有明显异常。
In this article, the proliferative responses of lymphocytes in 14 patients and 14 normal human lymphocytes were determined by trace-volume whole-blood, technetium-labeled thymidine incorporation. As a result, the proliferative response induced by PHA in tumor patients PBMC was significantly lower than that in normal controls (P<0.01). The levels of sIL-2R in the culture supernatant of 72 h lymphocytes induced by plasma (or serum) and PHA were detected by ELISA double antibody sandwich method. As a result, the level of sIL-2R in the lymphocyte culture supernatant of tumor patients was significantly lower than that of the normal control group. The level of sIL-2R was positively correlated with the lymphocyte proliferation reaction, and the correlation coefficient was very significant (Tr<0.01). The level of sIL-2R in cancer patients was significantly higher than that in normal controls (P<0.01). It shows that there are obvious abnormalities in the expression and release of IL-2R in T lymphocytes of tumor patients.